English
Back
Download
Log in to access Online Inquiry
Back to the Top
avatar
Jaguar8 commented on a stock · May 14, 2024 20:01

$89bio (ETNB.US)$ NEWS 89bio Initiates Phase 3 ENLIGHTEN-Cir...

NEWS
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
89bio has initiated the Phase 3 ENLIGHTEN-Cirrhosis trial for pegozafermin in patients with MASH and compensated cirrhosis (F4). This is the first FGF21 analog to reach this trial stage for this patient subset. The trial will involve 760 patients, assessing fibrosis regression at 24 months, potentially supporting accelerated approval in the U.S. and Europe. The trial's primary goal is to observe clinical outcome events for confirmatory or full approval. The ENLIGHTEN-Cirrhosis trial builds on promising Phase 2b results showing improvements in liver health markers, aiming to meet the urgent need for effective therapies in MASH with compensated cirrhosis.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
8744 Views
Comment
Sign in to post a comment
    avatar
    Jaguar8
    Spread kindness and love. Life is short. Don’t let greed eat you.
    8164
    Followers
    50
    Following
    93K
    Visitors
    Follow
    Heat List
    US
    SymbolMini ChartPrice
    TSLA
    Tesla
    -- 355.840
    NVDA
    NVIDIA
    -- 138.850
    INTC
    Intel
    -- 23.600
    GCL
    GCL Global
    -- 3.049
    NBIS
    NEBIUS
    -- 44.490
    Discussing
    Trump 2.0 Era: How will global markets evolve?
    🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
    MicroStrategy Q4 2024 earnings conference call
    Reassessing Chinese Assets
    Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.